Premium
Tocilizumab treatment for new onset refractory status epilepticus
Author(s) -
Jun JinSun,
Lee SoonTae,
Kim Ryul,
Chu Kon,
Lee Sang Kun
Publication year - 2018
Publication title -
annals of neurology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.764
H-Index - 296
eISSN - 1531-8249
pISSN - 0364-5134
DOI - 10.1002/ana.25374
Subject(s) - tocilizumab , medicine , status epilepticus , refractory (planetary science) , rituximab , adverse effect , epilepsy , lymphoma , disease , physics , psychiatry , astrobiology
We investigated the therapeutic potential of the interleukin‐6 receptor inhibitor tocilizumab in 7 patients with new onset refractory status epilepticus (NORSE) who remained refractory to conventional immunotherapy with rituximab (n = 5) or without rituximab (n = 2). Status epilepticus (SE) was terminated after 1 or 2 doses of tocilizumab in 6 patients with a median interval of 3 days from the initiation. They had no recurrence of SE during the observation. However, 2 patients experienced severe adverse events related to infection during the tocilizumab therapy. Further prospective controlled studies are warranted to validate the efficacy and safety of tocilizumab in patients with NORSE. Ann Neurol 2018;84:940–945